Upcoming Meetings: FDA Orthopedic and Rehabilitation Devices Panel
This article was originally published in The Gray Sheet
FDA Orthopedic and Rehabilitation Devices Panel: Scheduled to meet Nov. 20-21 at Hilton Hotel in Gaithersburg, Maryland to discuss two premarket approval applications for use of sodium hyaluronate-based products indicated for pain reduction and/or joint dysfunction in arthritic knees. One of the PMAs is for Biomatrix' Synvisc, which is sold in Canada and Europe. Open committee discussion is scheduled for the afternoon of Nov. 20 and the morning of Nov. 21...
You may also be interested in...
Strong top-line efficacy in pyruvate kinase deficiency patients who don’t receive regular transfusions looks approvable, analysts say, but Agios will await data in regularly transfused patients.
ICON survey finds payers increasingly use ICER reports at multiple ‘touchpoints’ during the drug evaluation and decision-making process and the most common use reported in 2020 was as a reference in rebate and pricing negotiations.
Results of a forthcoming APhA survey showed about one-third cannot store Pfizer/BioNTech's BNT162b2, but can handle Moderna's mRNA-1273.